In Brief: FDA's Dental Products Panel Plaque Subcommittee
This article was originally published in The Tan Sheet
Executive Summary
FDA's Dental Products Panel Plaque Subcommittee: Will meet Oct. 29-30 from 8:30 a.m. to 5 p.m. at the Holiday Inn, Gaithersburg, Md. On Oct. 29, the committee will continue its discussion of, and may vote on, the safety and effectiveness of C31-G xylitol and zinc citrate, as well as combinations including: menthol/thymol/eucalyptol/menthol salicylate; hydrogen peroxide/povidone-iodine; hydrogen peroxide/sodium citrate; and zinc chloride/sodium lauryl sulfate. The committee also will continue its discussion of the criteria for OTC antiplaque and antigingivitis combination drug products. On Oct. 30, the committee will address final formulation testing for antiplaque/antigingivitis products, and will receive assignments for the review of foreign marketing data supporting antiplaque and antigingivitis ingredients. The subcommittee last discussed these issues in May ("The Tan Sheet" May 12, pp. 4-7)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning